2021.02.17IR

AnGes’ Phase 1b Results of NF-kappa B Oligo DNA Decoy Administration in Subjects with Chronic Discogenic Low Back Pain Support Advancement into Phase 2 Clinical Study

2021.02.15IR

Consolidated Financial Report for the Fiscal Year 2020

2020.12.18IR

Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment

2020.12.15IR

EmendoBio Gene Editing Company Acquired by AnGes, Inc.

2020.11.13IR

FDA Allowance of IND Application For AV-001 for the Treatment of Hospitalized Patients with COVID-19

Learn more